title: Hepatic infarction following percutaneous ethanol injection therapy for hepatocellular carcinoma.
abstract: We report on two patients who developed hepatic infarction after undergoing percutaneous ethanol injection therapy (PEIT) for hepatocellular carcinoma (HCC). In both cases, liver function parameters deteriorated immediately after the ethanol injection, and enhanced computed tomography images showed a wedge-shaped avascular low-density area due to hepatic infarction. In one patient, PEIT was performed for a nodule treated with transcatheter arterial infusion (TAI) using a suspension of styrene maleic acid neocarzinostatin (SMANCS) 4 weeks before. In the other patient, TAI with SMANCS had been carried out 14 months previously for a different nodule in the same segment where the nodule treated with PEIT was located. When PEIT is used for patients with HCC who have previously undergone TAI, especially with SMANCS, PEIT may induce hepatic infarction.
authors.affiliation: Third Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Seki
authors.forename: M
authors.initials: M
authors.lastname: Wakabayashi
authors.forename: T
authors.initials: T
authors.lastname: Nakagawa
authors.forename: M
authors.initials: M
authors.lastname: Imamura
authors.forename: T
authors.initials: T
authors.lastname: Tamai
authors.forename: A
authors.initials: A
authors.lastname: Nishimura
authors.forename: N
authors.initials: N
authors.lastname: Yamashiki
authors.forename: A
authors.initials: A
authors.lastname: Okamura
authors.forename: K
authors.initials: K
authors.lastname: Inoue
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy*; D002406:Catheterization, Peripheral; D000431:Ethanol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007238:Infarction / Q000000981:diagnostic imaging / Q000209:etiology*; D015552:Injections, Intralesional; D008099:Liver / Q000098:blood supply* / Q000000981:diagnostic imaging; D008103:Liver Cirrhosis / Q000150:complications; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008299:Maleic Anhydrides / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D011137:Polystyrenes / Q000008:administration & dosage / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D009353:Zinostatin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D008299:Maleic Anhydrides; D011137:Polystyrenes; C035755:poly(maleic acid-styrene)neocarzinostatin; D000431:Ethanol; D009353:Zinostatin